Life threatening hepatotoxicity induced by Nilotinib

Area of Science:

• Hematology
• Pharmacology
• Oncology

Background:

• Tyrosine kinase inhibitors (TKIs) have significantly improved chronic myeloid leukemia (CML) survival rates.
• Adverse events (AEs) associated with TKIs can impede treatment adherence and patient quality of life.
• Effective management strategies for rare TKI-induced AEs are essential for long-term CML patient care.

Observation:

• A case of a 57-year-old woman with CML presented with rare, life-threatening hepatotoxicity (severe cytolysis and coagulopathy) during second-line Nilotinib therapy.
• The patient achieved an optimal molecular response despite developing severe drug-induced liver injury.
• This highlights the potential for severe AEs even with effective disease control.

Findings:

• The case underscores the challenge of managing severe AEs in CML patients undergoing TKI treatment.
• Sophisticated pharmacological monitoring and management approaches are necessary to mitigate risks.
• Successful management involved a multidisciplinary approach combining clinical expertise and literature review.

Implications:

• There is a critical need for enhanced monitoring protocols that include drug pharmacokinetics in addition to molecular response.
• Implementing such strategies can help prevent severe AEs, preserve treatment efficacy, and improve patient compliance.
• This approach is vital for optimizing the long-term outcomes and quality of life for CML patients.